201 related articles for article (PubMed ID: 35389018)
1. Clinicopathological features and prognosis of pyoderma gangrenosum in Korea: A single centre, retrospective, observational study over 20 years.
Kim YJ; Lee KH; Won CH; Chang SE; Lee MW; Choi JH; Lee WJ
Indian J Dermatol Venereol Leprol; 2023; 89(1):25-34. PubMed ID: 35389018
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum.
Ashchyan HJ; Butler DC; Nelson CA; Noe MH; Tsiaras WG; Lockwood SJ; James WD; Micheletti RG; Rosenbach M; Mostaghimi A
JAMA Dermatol; 2018 Apr; 154(4):409-413. PubMed ID: 29450453
[TBL] [Abstract][Full Text] [Related]
4. Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients.
Vacas AS; Torre AC; Bollea-Garlatti ML; Warley F; Galimberti RL
Int J Dermatol; 2017 Apr; 56(4):386-391. PubMed ID: 28295267
[TBL] [Abstract][Full Text] [Related]
5. Pyoderma gangrenosum: A clinico-epidemiological study.
Riyaz N; Mary V; Sasidharanpillai S; Roshin RA; Snigdha O; Latheef EN; Rahima S; Bindu V; Anupama RN; Sureshan DN; Sherjeena PV
Indian J Dermatol Venereol Leprol; 2017; 83(1):33-39. PubMed ID: 27549869
[TBL] [Abstract][Full Text] [Related]
6. Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases.
Sasor SE; Soleimani T; Chu MW; Cook JA; Nicksic PJ; Tholpady SS
J Wound Care; 2018 Jan; 27(Sup1):S4-S8. PubMed ID: 29334018
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Argüelles-Arias F; Castro-Laria L; Lobatón T; Aguas-Peris M; Rojas-Feria M; Barreiro-de Acosta M; Soto-Escribano P; Calvo-Moya M; Ginard-Vicens D; Chaparro-Sánchez M; Hernández-Durán M; Castro-Senosiain B; Fernández-Villaverde A; García-Sánchez V; Domínguez-Muñoz E; Caunedo-Álvarez A; Herrerías-Gutiérrez JM
Dig Dis Sci; 2013 Oct; 58(10):2949-54. PubMed ID: 23828140
[TBL] [Abstract][Full Text] [Related]
8. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions.
Bennett ML; Jackson JM; Jorizzo JL; Fleischer AB; White WL; Callen JP
Medicine (Baltimore); 2000 Jan; 79(1):37-46. PubMed ID: 10670408
[TBL] [Abstract][Full Text] [Related]
9. Pyoderma gangrenosum--a review of 24 cases observed over 10 years.
Pereira N; Brites MM; Gonçalo M; Tellechea O; Figueiredo A
Int J Dermatol; 2013 Aug; 52(8):938-45. PubMed ID: 23676016
[TBL] [Abstract][Full Text] [Related]
10. Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013.
Barbosa NS; Tolkachjov SN; El-Azhary RA; Davis MD; Camilleri MJ; McEvoy MT; Bridges AG; Wetter DA
J Am Acad Dermatol; 2016 Nov; 75(5):931-939. PubMed ID: 27473454
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center.
Giraudo F; Miraglia E; Garbi ML; Yantorno M; Maradeo MR; Correa GJ; Tufare F
Rev Esp Enferm Dig; 2021 Oct; 113(10):691-697. PubMed ID: 33267595
[TBL] [Abstract][Full Text] [Related]
12. [Pyoderma gangrenosum: a report of 15 cases and review of the literature].
Suárez-Pérez JA; Herrera-Acosta E; López-Navarro N; Vilchez-Márquez F; Prieto JD; Bosch RJ; Herrera E
Actas Dermosifiliogr; 2012 Mar; 103(2):120-6. PubMed ID: 21782147
[TBL] [Abstract][Full Text] [Related]
13. Mucocutaneous pyoderma gangrenosum: a case report and literature review.
Đorđević Betetto L; Točkova O; Bergant Suhodolčan A
Acta Dermatovenerol Alp Pannonica Adriat; 2022 Mar; 31(Suppl):S10-S13. PubMed ID: 35339135
[TBL] [Abstract][Full Text] [Related]
14. Neutrophilic dermatoses: a review of current treatment options.
Cohen PR
Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
[TBL] [Abstract][Full Text] [Related]
15. Pyoderma gangrenosum: a review with special emphasis on Latin America literature.
Rodríguez-Zúñiga MJM; Heath MS; Gontijo JRV; Ortega-Loayza AG
An Bras Dermatol; 2019; 94(6):729-743. PubMed ID: 31789268
[TBL] [Abstract][Full Text] [Related]
16. Pyoderma Gangrenosum: A Retrospective Study of Clinical Charac-teristics, Comorbidities, Response to Treatment and Mortality Related to Prednisone Dose.
Schøsler L; Fogh K; Bech R
Acta Derm Venereol; 2021 Apr; 101(4):adv00431. PubMed ID: 33686448
[TBL] [Abstract][Full Text] [Related]
17. Neutrophilic dermatoses: Pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses.
Ashchyan HJ; Nelson CA; Stephen S; James WD; Micheletti RG; Rosenbach M
J Am Acad Dermatol; 2018 Dec; 79(6):1009-1022. PubMed ID: 29653213
[TBL] [Abstract][Full Text] [Related]
18. Bullous pyoderma gangrenosum as the presenting sign of fatal acute myelogenous leukemia.
Fox LP; Geyer AS; Husain S; Grossman ME
Leuk Lymphoma; 2006 Jan; 47(1):147-50. PubMed ID: 16321840
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
[TBL] [Abstract][Full Text] [Related]
20. [Management of pyoderma gangrenosum. An update on clinical features, diagnosis and therapy].
Trémezaygues L; Schmaltz R; Vogt T; Reichrath J
Hautarzt; 2010 Apr; 61(4):345-53; quiz 354-5. PubMed ID: 20361320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
